The Global Gastrointestinal Stent Market is expected to reach USD 600 million by 2026 from USD 457 million in 2021, at a CAGR of 5.6% during the forecast period of 2021 to 2026. Gastrointestinal (GI) stents are designed for palliative therapy for various diseases causing obstruction in the GI tract. GI stents have a major role in the recanalization of gastrointestinal (GI) tumors and postoperative leak sealing. Other potential applications of GI stents are drug-eluting devices, tissue modeling for benign conditions, and GI tract drainage/anastomosis. Gastrointestinal stent market growth can be attributed to the rising prevalence of GI cancers and other digestive diseases, and changing lifestyles, increasing healthcare expenditure on gastrointestinal procedures, and increasing preference for minimally invasive surgeries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167758126

Browse in-depth TOC on "Gastrointestinal Stent Market”

197 – Tables

50 – Figures

233 – Pages

Key Player

The prominent players operating in this market include Boston Scientific Corporation (US), Cook Group (US), Medtronic plc. (Ireland), ELLA-CS, s.r.o. (Czech Republic), Becton, Dickinson and Company (US), Merit Medical Systems (US), CONMED Corporation (US), Cantel Medical (US), Olympus Corporation (Japan), Taewoong Medical (South Korea), Micro-Tech (Nanjing) Co., Ltd. (China), Endo-Flex GmbH (Germany), MI-Tech (South Korea), Hobbs Medical Inc. (US), QualiMed (Germany), UK Medical (UK), CITEC (China), Medorah Meditek Pvt. Ltd. (India), Leufen Medical GmbH (Germany), and BCM Corporation (South Korea). These players adopted the strategies of new product launches, partnerships, agreements, and acquisitions to expand their presence in the global gastrointestinal stent market.

Drivers: Rise in the incidence of gastrointestinal cancers, IBD, and other digestive diseases

Gastrointestinal cancer is one of the leading causes of death worldwide. In the past few years, there has been a steep rise in morbidity and mortality from chronic diseases such as esophageal cancer, colorectal cancer, and gastrointestinal-related critical disorders. According to the International Agency for Research on Cancer (IARC), in 2018, gastrointestinal cancers accounted for 26% of the global burden of cancer incidence and 35% of all cancer-related deaths.

According to the WHO, gastrointestinal cancers, such as colorectal cancer, were responsible for 935,000 deaths globally in 2020, and stomach cancer accounted for 769,000 deaths. Colorectal cancer was the third most common cancer worldwide with 1.93 million new cases diagnosed

Enquiry Before Buying this Report:

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=167758126

Restraints: High cost of the procedure and limited reimbursement in developing countries

In recent years, the cost of healthcare has increased significantly across the globe, and the prices of medical devices, including GI stent, has also increased. According to a study reported by PubMed.gov in May 2021, the average price of an endoscopic stenting procedure is about USD 43,798.06. Healthcare providers and payers in developing countries, such as India and Brazil, have low financial resources to invest in such a costly procedure.

The Esophageal Stents segment is estimated to grow at the highest CAGR in the gastrointestinal stent, by products, in 2020

Based on product, the gastrointestinal stent market is segmented into biliary stents, duodenal stents, colonic stents, pancreatic stents, and esophageal stents. The biliary stents segment accounted for the largest share in 2020. The Esophageal Stents segment is estimated to grow at the highest CAGR during the forecast period. The increasing prevalence of bile duct cancer and chronic liver disease is one of the prominent factors responsible for the growth of the biliary stents segment. Moreover, The increasing incidence of biliary diseases and the growth in the number of surgical procedures for the treatment of biliary diseases are the other major factors that are expected to support the growth of this market segment during the forecast period.

The self-expanding metal stent segment will dominate the gastrointestinal stent market, by material during the forecast period

Based on material, the global market is segmented into self-expanding metal stents and plastic stents. Self-expanding metal stents are further sub-segmented into nitinol, stainless steel, and other metal stents. Factors such as the increased demand for Self-expanding metal stents due to advantages offered by these stents such as ease of insertion, a lower possibility of dislodgment or migration, longer patency. Metal stents are usually made of stainless steel, nitinol, cobalt-chromium, and platinum-chromium with or without coating. Self-expanding metal stents are used for the treatment of benign gastrointestinal leaks and perforations. These stents act as a support to keep the gastrointestinal tract open and provide easy unobstructed drainage of food and water.

The Gastrointestinal Cancers segment to register the fastest growth in the gastrointestinal stent market, by application, during the forecast period

Based on application, the global market is segmented into biliary diseases, irritable bowel syndrome, and gastrointestinal cancers. The gastrointestinal cancers segment is further categorized into colorectal cancer, stomach cancer, esophageal cancer, and pancreatic cancer. The biliary diseases segment accounted for the largest share in 2020. The gastrointestinal cancers segment is projected to have the highest CAGR during the forecast period. The growth of this segment is attributed to the increased prevalence and incidences of gastrointestinal cancers. For instance, According to a report by the American Cancer Society, Colorectal Cancer Facts & Figures 2020-2022, in 2020, there were an estimated 104,610 new cases of colon cancer and 43,340 cases of rectal cancer diagnosed in the US.

Hospitals and clinics are the largest end users of gastrointestinal stent

Based on end users, the gastrointestinal stent market is segmented into hospitals and clinics and ambulatory surgical centers. The hospitals and clinics segment accounted for the largest share of in 2020. The large share of this segment can be attributed to the large number of endoscopic retrograde cholangio-pancreatography (ERCP) and percutaneous transhepatic cholangiography (PTC) procedures performed in hospitals for different disease indications, favorable reimbursement scenarios, and increased government initiatives to provide quality treatment for gastrointestinal diseases.

North America was the largest regional market for Gastrointestinal Stent market in 2020

The Gastrointestinal Stent market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latina America, and the Middle East and Africa. In 2020, North America accounted for the largest share. The large share of North America in the global market is attributed to the rising geriatric population, high incidence of gastrointestinal diseases, favourable reimbursement scenario, and presence of key market players. Some of the major players in this market are Boston Scientific Corporation (US), C.R. Bard (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), CONMED Corporation (US), Cook Medical (US), Cantel Medical (US), and Hobbs Medical (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=167758126

Recent Developments:

  • In November 2020, Boston Scientific Corporation (US) has received 510(k) approval from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures caused by esophageal cancer.
  • In October 2020, Olympus Corporation (Japan) launched HANAROSTENT Esophagus TTS Self-expanding Metal Stents (SEMS) made by MI-Tech and distributed exclusively through Olympus in the US.
  • In June 2019, Merit Medical System Inc. (US) acquired Brightwater Medical inc. (US) with an upfront payment of USD 35 million. Brightwater Medical Inc. has received the FDA clearance for the ConvertX biliary stent device.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/gastrointestinal-gi-stent-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/gastrointestinal-gi-stent.asp